MeiraGTx Holdings plc Ordinary Shares (MGTX)
Stock · NASDAQ · Health Care
$9.29as of 10/16/2026
Price chart
Active signals
MGTX Signal Track Record
How signals performed across all stocks →What MGTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.8% | 47% | October 7, 2026 |
| Bollinger Band Breakout | 25 | +1.9% | 60% | August 7, 2026 |
| Bollinger Band Breakdown | 16 | +2.6% | 63% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -3.4% | 40% | March 16, 2026 |
| Any 20-session window (baseline) | +0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MGTX
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 393
- Website
- meiragtx.com/
Fundamentals
- 1-day range
- $9.38$9.92
- Market cap
- $1.18B
- P/E (trailing)
- 11.93
- P/E (forward)
- -6.49
- EPS (trailing)
- $0.71
- Dividend yield
- —
- Beta
- 1.05
- Avg. volume
- 774.8K
How MeiraGTx Holdings plc Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
MeiraGTx Holdings plc Ordinary Shares Competitors
Chosen by industry and closest market cap.
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- CGEMCullinan Therapeutics Inc. Common Stock$12.93▼ 7.64%Market cap $1.10BP/E —$6.73$23.19
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| CGEM Cullinan Therapeutics Inc. Common Stock | $1.10B | — | $12.93 | ▼ 7.64% | $6.73$23.19 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Goldman Sachs Initiates Coverage On MeiraGTx Holdings with Neutral Rating, Announces Price Target of $16benzinga · 9/24/2026
- Goldman Sachs Initiates Coverage On MeiraGTx Holdings with Neutral Rating, Announces Price Target of $16Benzinga · 9/24/2026
- MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsYahoo · 9/23/2026
Insider Activity
Insider Actions →- Stuart Naylor · October 6, 2026 · Sale27.7K @ $10.64
- SEBULSKY ALAN · September 23, 2026 · Grant100.0K
- Alexandria Forbes · August 18, 2026 · Sale62.0K @ $13.86
- Richard Giroux · July 21, 2026 · Sale56.0K @ $12.51
- Stuart Naylor · July 7, 2026 · Sale25.1K @ $14.9
- Stuart Naylor · July 7, 2026 · Sale2.5K @ $13.86
- Yu Debra · June 11, 2026 · Grant60.0K
- Hukkelhoven Ellen · June 11, 2026 · Grant60.0K
- Keith R. Harris · June 11, 2026 · Grant106.4K
- Mendoza Neil · June 11, 2026 · Grant66.6K
- Nicole Seligman · June 11, 2026 · Grant60.0K
- SHENK THOMAS E · June 11, 2026 · Grant69.7K
- Joseph Edelman · June 11, 2026 · Grant60.0K
- Keith R. Harris · June 10, 2026 · Option Exercise75.0K
- Richard Giroux · May 27, 2026 · Gift7.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs initiates MeiraGTx coverage with Neutral rating
Goldman Sachs has started covering MeiraGTx, assigning a Neutral rating and a price target of $16. This new analyst view comes as the company also appointed Alan M. Sebulsky to its board of directors. The stock is currently trading near its 52-week low, providing context for the firm's initial assessment.
Goldman Sachs initiates MeiraGTx coverage with Neutral rating. Goldman Sachs has started covering MeiraGTx, assigning a Neutral rating and a price target of $16. This new analyst view comes as the company also appointed Alan M. Sebulsky to its board of directors. The stock is currently trading near its 52-week low, providing context for the firm's initial assessment.